LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Lixte Biotechnology Holdings, Inc. (LIXT)
NASDAQ:AMEX Investor Relations:
lixte.com/investor_information_02.php
Company Research
Source: Yahoo! Finance
Holdings, Inc . (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Schellens brings to LIXTE more than 25 years of clinical experience as a medical oncologist, pharmacologist and clinical pharmacologist, including more than two decades developing and bringing new drugs to market. He assumes the CMO role at LIXTE effective August 1, 2024, succeeding James S. Miser, M.D., who is leaving the Company after serving in this capacity since 2020. “Dr. Schellens is a widely respected medical professional who has been at the forefront of oncology throughout his career,” said Bas van der Baan, LIXTE's Chief Executive Officer. “He brings a highly relevant background to LIXTE, and we are fortunate in attracting him to our organization, as we continue to make progress with
Show less
Read more
Impact Snapshot
Event Time:
LIXT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LIXT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LIXT alerts
High impacting Lixte Biotechnology Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
LIXT
News
- LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical TrialGlobeNewswire
- LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial [Yahoo! Finance]Yahoo! Finance
- LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical TrialGlobeNewswire
- Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System [Yahoo! Finance]Yahoo! Finance
- Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune SystemGlobeNewswire
LIXT
Sec Filings
- 6/14/24 - Form 8-K
- 6/14/24 - Form 8-K
- 6/5/24 - Form 8-K
- LIXT's page on the SEC website